Interpretation and reflection on the WHO Preferred Product Characteristics for New Tuberculosis Vaccines

doi:10.19982/j.issn.1000-6621.20230318

Abstract

Abstract:

Despite significant advancements in global research, no new tuberculosis (TB) vaccine has been successfully licensed so far. Development of new TB vaccines is urgently needed to end the prevalence of TB, therefore, the World Health Organization (WHO) published the report “WHO Preferred Product Characteristics for New Tuberculosis Vaccines” in 2018. This document outlines the preferences of WHO for new TB vaccines. The authors interpret the document and analyze the direction of development for new TB vaccines, in hope to provide valuable insights for vaccine researchers and formulate new TB vaccines more adaptable to practical needs.

Key words: Mycobacterium tuberculosis, Infection, Vaccines

CLC Number:

R52
R186

Dong Jiaxin, Zhao Aihua, Xia Huanzhang, Xu Miao. Interpretation and reflection on the WHO Preferred Product Characteristics for New Tuberculosis Vaccines[J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1016-1020. doi: 10.19982/j.issn.1000-6621.20230318

References 26

[1]	蒋加庆, 景辉. 卡介苗生产工艺、质量、使用现状及新型结核病疫苗的发展趋势. 中国生物制品学杂志, 2021, 34(10): 1260-1268. doi:10.13200/j.cnki.cjb.003459.
[2]	World Health Organization. WHO preferred product characteristics for new tuberculosis vaccines. Gevena: World Health Organization, 2018.
[3]	Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med, 2011, 17(2):189-194. doi:10.1038/nm.2285. pmid: 21258338
[4]	Lin PL, Dietrich J, Tan E, et al. The multistage vaccine H 56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest, 2012, 122(1):303-314. doi:10.1172/JCI46252.
[5]	Billeskov R, Lindenstrøm T, Woodworth J, et al. High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis. Front Immunol, 2018, 8:1973. doi:10.3389/fimmu.2017.01973.
[6]	Hoang T, Aagaard C, Dietrich J, et al. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One, 2013, 8(12): e80579. doi:10.1371/journal.pone.0080579.
[7]	Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med, 2014, 20(1):75-79. doi:10.1038/nm.3412. pmid: 24336248
[8]	Lawal IO, Abubakar S, Ankrah AO, et al. Molecular Imaging of Tuberculosis. Semin Nucl Med, 2023, 53(1):37-56. doi:10.1053/j.semnuclmed.2022.07.001.
[9]	Minassian AM, Satti I, Poulton ID, et al. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis, 2012, 205(7):1035-1042. doi:10.1093/infdis/jis012. pmid: 22396610
[10]	Harris SA, Meyer J, Satti I, et al. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. J Infect Dis, 2014, 209(8):1259-1268. doi:10.1093/infdis/jit647. pmid: 24273174
[11]	Minhinnick A, Harris S, Wilkie M, et al. Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity. J Infect Dis, 2016, 213(5):824-830. doi:10.1093/infdis/jiv482. pmid: 26450421
[12]	Lu JB, Chen BW, Wang GZ, et al. Recombinant tuberculosis vaccine AEC/BC 02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect, 2015, 48(6):597-603. doi:10.1016/j.jmii.2014.03.005.
[13]	Guo X, Lu J, Li J, et al. The Subunit AEC/BC 02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs. Vaccines (Basel), 2022, 10(12):2164. doi:10.3390/vaccines10122164.
[14]	Eurosurveillance editorial team. WHO revised definitions and reporting framework for tuberculosis. Euro Surveill, 2013, 18(16):20455.
[15]	Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019, 381(25):2429-2439. doi:10.1056/NEJMoa1909953.
[16]	Roordink D, Williams A, Fritzell B, et al. The TB vaccine development pathway-An innovative approach to accelerating global TB vaccine development. Tuberculosis (Edinb), 2021, 126:102040. doi:10.1016/j.tube.2020.102040.
[17]	Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M.tuberculosis Infection with H4:IC 31 Vaccine or BCG Revaccination. N Engl J Med, 2018, 379(2):138-149. doi:10.1056/NEJMoa1714021.
[18]	Luabeya AK, Kagina BM, Tameris MD, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC 31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine, 2015, 33(33):4130-4140. doi:10.1016/j.vaccine.2015.06.051.
[19]	Suliman S, Luabeya AKK, Geldenhuys H, et al. Dose Optimization of H56:IC 31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. Am J Respir Crit Care Med, 2019, 199(2):220-231. doi:10.1164/rccm.201802-0366OC.
[20]	中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi:10.3969/i.issn.1000-6621.2020.08.001.
[21]	Xia L, Xu M, Li F, et al. High accuracy of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 skin test for the detection of tuberculosis infection: a phase Ⅲ, multi-centered, double-blind, hospital-based, randomized controlled trial. Int J Infect Dis, 2023, 126:98-103. doi:10.1016/j.ijid.2022.11.014.
[22]	陈柠, 孙琳, 申阿东, 等. 卡介苗接种后发生感染的可能原因研究现况. 中国防痨杂志, 2020, 42(8):869-873. doi:10.3969/j.issn.1000-6621.2020.08.017.
[23]	Cobelens F, Suri RK, Helinski M, et al. Accelerating research and development of new vaccines against tuberculosis: a global roadmap. Lancet Infect Dis, 2022, 22(4): e108-e120. doi:10.1016/S1473-3099(21)00810-0.
[24]	The European and Developing Countries Clinical Trials Partnership. EDCTP and AIGHD launched a global roadmap for tuberculosis vaccine development[EB/OL].[2023-07-10]. http://www.edctp.org/news/edctp-and-aighd-launched-a-global-roadmap-for-tuberculosis-vaccine-development/#.
[25]	Clark RA, Mukandavire C, Portnoy A, et al. The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study. Lancet Glob Health, 2023, 11(4): e546-e555. doi:10.1016/S2214-109X(23)00045-1.
[26]	卢锦标, 徐苗. 结核灭活疫苗的临床研究进展. 微生物学免疫学进展, 2019, 47(4):69-74. doi:10.1016/S2214-109X(23)00045-1.